NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2025
0mins
Source: Newsfilter
Fast Track Designation: The FDA has granted Fast Track designation to NKGen's troculeucel, an autologous NK cell therapy for moderate Alzheimer's disease, which will expedite its development and review process, potentially leading to faster market access.
Clinical Development Update: NKGen is currently enrolling patients in a Phase 2a trial for troculeucel and anticipates sharing updated clinical data by the end of 2025, following promising results from its Phase 1 trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
